Sean P. Nolan has been appointed executive vice president and chief business officer at InterMune, Inc. In this newly created position, Mr. Nolan will lead the establishment of InterMune's U.S. commercial, business development and global marketing groups. He will also oversee Canadian operations and the company's manufacturing operations and supply chain management. Mr. Nolan will report to Dan Welch, chairman, chief executive officer and president of InterMune.
Mr. Nolan joins the company from Reata Pharmaceuticals, where he most recently served as vice president and chief commercial officer and built a commercial operation to support the company's lead product.
Mr. Welch said, "Sean will play a key role in InterMune's future as our Esbriet sales continue to grow globally, we move closer to the anticipated approval and launch of Esbriet [a treatment for idiopathic pulmonary fibrosis] in the U.S. and as we prepare to develop our business. I am confident that Sean will provide the broad and deep commercial and business experience, energy and drive that are essential during this exciting period of growth and change for our company."